Spruce Street Capital
ATTO

Spruce Street Capital’s Attovia Therapeutics ATTO Stock Holding History

Spruce Street Capital’s Portfolio ATTO Stock Details ATTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.91M Buy
+228,295
New +$4.81M 0.62% 31

Other funds holding ATTO

Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $132M AUM 92.09% 1-Year Est. Return

Spruce Street Capital's ATTO Position: Q3 2026 in Review

Spruce Street Capital opened a new position in Attovia Therapeutics (ATTO) in Q3 2026: 228,295 shares worth $3.91M. The stake represents 0.62% of the portfolio and ranks #31 among its holdings.

27 funds tracked by Wall St. Rank hold ATTO as of Q3 2026.

  • Spruce Street Capital held 228,295 shares of Attovia Therapeutics worth $3.91M as of Q3 2026.
  • Attovia Therapeutics was a new Spruce Street Capital position in Q3 2026.
  • Attovia Therapeutics made up 0.62% of Spruce Street Capital's portfolio in Q3 2026, its #31 holding.
  • 27 funds tracked by Wall St. Rank held Attovia Therapeutics as of Q3 2026.

Based on Spruce Street Capital's 13F filing for Q3 2026, filed 13 Nov 2026.